Laurie Lajoie

Assistant professor

Université de Tours Faculté de Pharmacie de Tours

France

Research Interests

Explore related searches

Professors in France Professors in Immunology Immunology professors in France

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Laurie Lajoie is an Assistant Professor at Université de Tours Faculté de Pharmacie de Tours in France. Her research focuses on innovative therapeutic strategies in oncology and infectious diseases, including antibody engineering and cell targeting mechanisms. Recent publications highlight her work on enhancing antibody-dependent cellular cytotoxicity and developing novel therapies for cancer and viral infections.

Articles (7)

Year:

2024

Year:

2024

Year:

2022

Year:

2022

Year:

2022

Year:

2020

Year:

2020

Collaborators (7)

Olivier Reynard

external associate professor

University of Lyon

FRANCE

View details

martin villalba

CNRS Délégation Languedoc-Roussillon

FRANCE

View details

Anne di Tommaso

Université de Tours

FRANCE

View details

Cyrille Mathieu

Université Claude Bernard Lyon 1

FRANCE

View details

Deborah Le Pennec

Université de Tours

FRANCE

View details

aude mallavialle

Institut de Recherche en Cancérologie de Montpellier

FRANCE

View details

Philippe Gatault

Assistant professor

FRANCE

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Laurie Lajoie

Research Interests

Explore related searches

Contact this professor

About

Articles (7)

Specific Cell Targeting by <i>Toxoplasma gondii</i> Displaying Functional Single-Chain Variable Fragment as a Novel Strategy; A Proof of Principle

A novel Fc-engineered cathepsin D-targeting antibody enhances ADCC, triggers tumor-infiltrating NK cell recruitment, and improves treatment with paclitaxel and enzalutamide in triple-negative breast cancer

Nebulized fusion inhibitory peptide protects cynomolgus macaques from measles virus infection

Anticalin N- or C-Terminal on a Monoclonal Antibody Affects Both Production and In Vitro Functionality

Adcitmer <sup>®</sup> , a new CD56‐targeting monomethyl auristatin E‐conjugated antibody, is a potential therapeutic approach in Merkel cell carcinoma*

The FcγRIIIA‐158 VV genotype increased the risk of post‐transplant lymphoproliferative disorder in T‐cell‐depleted kidney transplant recipients – a retrospective study

The Proteolytic Cleavage of Therapeutic Monoclonal Antibody Hinge Region: More Than a Matter of Subclass.

Collaborators (7)

Olivier Reynard

martin villalba

Anne di Tommaso

Cyrille Mathieu

Deborah Le Pennec

aude mallavialle

Philippe Gatault

Make your next move.